Setback for Cladribin in the EU

A board to discuss future MS therapies in early stage (Phase I or II) trials.

Setback for Cladribin in the EU

Postby Frank » Fri Sep 24, 2010 6:18 am

Regulators mainly took issue with cases of lymphopenia, a lack of a certain type of white blood cells, and with the risk of cancer

Treatment: Gilenya since 01/2011, CCSVI both IJV ballooned 09/2010, Tysabri stopped after 24 Infusions and positive JCV antibody test, after LDN, ABX Wheldon Regime for 1 year.
Family Elder
Posts: 543
Joined: Wed Jan 03, 2007 3:00 pm
Location: Germany


Return to Drug Pipeline

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service